*To the Editor*:

We read with great interest the recent publication by Van der Feen and colleagues ([@bib1]) highlighting that RVX-208 could normalize the hyperproliferative, apoptosis-resistant, and proinflammatory phenotype of microvascular endothelial cells and smooth muscle cells isolated from patients with pulmonary arterial hypertension (PAH). A previous study demonstrated that low-plasma high-density lipoprotein cholesterol (HDL-C) was associated with higher mortality and clinical worsening outcomes, including hospitalization and lung transplantation in the patients with PAH ([@bib2]). Administration of RVX-208 in the patients with coronary artery disease for 12 weeks was significantly associated with modulation of lipids metabolism, including increases in HDL-C level and concentration of large HDL particles ([@bib3]). Hence, we considered whether, first, the change of HDL-C would be one feasible clinical biomarker to reflect the responsiveness of drugs or prognostic value in the patients with PAH. For example, the enhancement of HDL-C in plasma through RVX-208 treatment would improve the clinical outcomes in patients with PAH, and second, based on the beneficial effects of RVX-208 on the amelioration of vascular remodeling, pulmonary hemodynamics, and right ventricle in different preclinical models of PAH ([@bib1]), the casual link among these observed outcomes, efficacy of RVX-208 therapy, and the change of HDL-C level or HDL components could be worthy of further investigation. Metabolic disorders characterized by increases of proinflammatory cytokine IL-6 level in lung and circulating leptin could exacerbate pulmonary hypertension as a result of left heart disease (PH-LHD), and patients diagnosed with this type of PAH have more severe symptoms and worse prognosis relative to patients with LHD alone ([@bib4]). Notably, in light of pulmonary vascular remodeling in such a novel preclinical model of PH-LHD relieved by metformin though improvement of metabolic states and decrease of inflammation, and positive effects of RVX-208 on the regulation of both inflammation and metabolism ([@bib3], [@bib4]), we thought that providing more insights about the efficacy of RVX-208 in PH-LHD might be more favorable to its clinical use. Epigenetic regulation plays a key role in the pathogenesis of PAH, such as drug/toxin susceptibility, female predominance, and quasimalignant lung vessel cell growth ([@bib5]). In view of BET protein BRD4 (bromodomain-containing protein 4) as an epigenetic driver of inflammation and atherogenesis, the reduction of vascular inflammation *in vitro* and major adverse cardiac events in the patients with cardiovascular disease by the administration of RVX-208 has been considered to rely on a BET-dependent epigenetic mechanism ([@bib6]). Therefore, we considered that clarifying additional epigenetic mechanisms underlying the therapeutic process of RVX-208 in PAH might be in favor of identifying putative biomarkers and risk or resilience factors for making new-type prevention and treatment to answer epigenetic-sensitive clinical challenges in PAH.
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